Valine alpha-ketoglutarate

Synopsis

Valine Alpha-Ketoglutarate

1. Identity and Chemical Nature

1.1 The Two Components

The term Valine alpha-ketoglutarate (sometimes abbreviated VAKG or Val-AKG) refers to a dietary supplement preparation that combines two biochemically related compounds: L-valine and alpha-ketoglutarate (AKG). The combination is conceptually grounded in a central enzymatic reaction in amino acid catabolism — the transamination of valine that directly consumes AKG as an amino-group acceptor — but as a standalone, commercially named ingredient, it belongs to the broader class of amino acid–alpha-keto acid conjugate supplements, analogous to the better-studied arginine alpha-ketoglutarate (AAKG) and ornithine alpha-ketoglutarate (OKG).

L-Valine: Valine (symbol Val or V) is an α-amino acid that is used in the biosynthesis of proteins. Its systematic IUPAC name is 2-amino-3-methylbutanoic acid (also written as 2-aminoisovaleric acid), with the CAS number 72-18-4. Leucine (Leu), isoleucine (Ile), and valine (Val) are essential amino acids and are collectively referred to as branched chain amino acids (BCAAs) because they have branched structures in their side chains and uniquely share two of the initial metabolic pathways. Valine cannot be de novo synthesized by animals, and it must be obtained through protein degradation from diet, such as grains and fish meal. Unlike D-valine, which forms bacterial cell walls, L-valine is more widely used to synthesize proteins in the body.

Alpha-ketoglutarate (AKG): AKG carries the CAS number 328-50-7 and has synonyms including α-KGA, NSC 17391, and 2-Oxoglutaric Acid. Alpha-ketoglutaric acid (AKG) is a ketone derivative of the organic compound glutaric acid. Its molecular formula in the di-anionic (deprotonated) form is C₅H₄O₅²⁻ (PubChem CID 164533), and its linear structural formula is HOOCCH₂CH₂COCOOH. AKG is used in dietary supplements as a direct precursor for glutamine and glutamate.

1.2 Common Supplement Forms and Preparations

In the supplement industry, valine and AKG are most frequently combined as a salt or co-formulation. AKG itself is commercially available in several forms: some products contain alpha-ketoglutarate along with other substances, such as arginine, ornithine, and calcium. The calcium salt (Ca-AKG) is a particularly studied form; the calcium form (Ca-AKG) was developed to improve the bioavailability and stability of AKG, making it particularly interesting for therapeutic applications. AKG is used nowadays as a component of solutions for infusion, formulations used in wound healing, or as a dietary supplement. In combination with valine specifically, preparations are marketed primarily in capsule and powder forms, often positioned within BCAA or "amino-acid complex" products. The purity of research-grade AKG, as supplied by chemical vendors, is typically ≥95–99%.

1.3 Natural Dietary Sources

Both components are endogenous and widely present in food. BCAAs are important nutrients found in protein sources such as meat, dairy, and legumes. Valine can be obtained naturally in various protein-rich meals derived from plant and animal sources. AKG is an endogenous metabolic intermediate that arises continuously from cellular energy metabolism; it is not typically enumerated as a discrete dietary constituent in standard food composition tables, but it can be detected in fermented foods and in the body fluids of animals consuming high-protein diets.

2. Traditional and Historical Use

As a defined dietary supplement combination, "valine alpha-ketoglutarate" has no documented history in pre-modern herbal or traditional medicine. Neither valine nor alpha-ketoglutaric acid was known as discrete chemical entities before the development of modern biochemistry in the 19th and 20th centuries. Valine was first isolated from pancreatic digests by Emil Fischer in the early 20th century, and AKG was characterized as a Krebs cycle intermediate following Hans Krebs's seminal work on the tricarboxylic acid cycle in 1937.

The use of AKG in a quasi-clinical context originated in clinical nutrition and surgical care from the 1970s onward, primarily in Europe. AKG is used during cardiac operations in order to avoid disturbances of blood flow and pressure, or in patients after surgery or trauma to prevent muscle breakdown. A few studies published in the 1980s and 1990s in humans suggested the potential benefits of AKG in muscle growth, wound healing, and in promoting faster recovery after surgery.

Ornithine alpha-ketoglutarate (OKG), a closely related compound, was developed in France as a parenteral and enteral nutrition additive specifically for use in burn patients and post-surgical nutritional support during this era. The research tradition surrounding OKG informed the later interest in valine's interaction with AKG. The specific pairing of valine with AKG as a marketed supplement formulation is a development of the 1990s–2000s sports nutrition industry, borrowing from the AAKG and OKG literature. There is no ethnobotanical, Ayurvedic, traditional Chinese medicine, or other classical herbal tradition associated with this compound.

3. Key Constituents and Established Mechanisms of Action

3.1 Alpha-Ketoglutarate as Krebs Cycle Intermediate

Alpha-ketoglutarate (AKG) is a molecule that has a central role in the Krebs cycle, determining the overall rate of the citric acid cycle of the organism, and is also a nitrogen scavenger in the body. It is formed via oxidative decarboxylation of isocitrate by isocitrate dehydrogenase (IDH), oxidative deamination of glutamate by glutamate dehydrogenase, or by pyridoxal phosphate-dependent transamination. Alpha-ketoglutaric acid is decarboxylated to succinyl-CoA by alpha-ketoglutarate dehydrogenase, a rate-limiting step in the citric acid cycle.

3.2 The Valine–AKG Transamination Reaction

The biochemical rationale for combining valine with AKG is rooted in BCAA catabolism. The first process of BCAA catabolism is catalyzed by branched chain aminotransferase (BCAT), and the second process is catalyzed by branched chain α-keto acid dehydrogenase (BCKDH); these are common to all three BCAAs. BCAA aminotransferases (BCATs) catalyze the first step of BCAAs catabolism, in which the transamination of valine, leucine, and isoleucine to α-ketoisovalerate (KIV), α-ketoisocaproate (KIC), and α-keto-β-methylvalerate (KMV), respectively, occurs. In this reaction, valine donates its amino group to AKG, generating alpha-ketoisovalerate (the keto-analogue of valine) and glutamate. Each BCAA forms a distinct alpha-keto acid due to a transamination process involving a BCAA aminotransferase and alpha-ketoglutarate. This reaction is reversible, meaning that a supply of exogenous AKG can theoretically support the re-amination of valine's keto-acid analog back to valine.

Like other branched-chain amino acids, the catabolism of valine starts with the removal of the amino group by transamination, giving alpha-ketoisovalerate, an alpha-keto acid, which is converted to isobutyryl-CoA through oxidative decarboxylation by the branched-chain α-ketoacid dehydrogenase complex. This is further oxidised and rearranged to succinyl-CoA, which can enter the citric acid cycle and provide direct fuel in muscle tissue.

3.3 AKG as Nitrogen Scavenger and Precursor for Glutamine and Glutamate

AKG can be rapidly converted into glutamate through the transamination by glutamate dehydrogenase, and further into glutamine through the amination by glutamine synthase. This nitrogen-buffering capacity is pharmacologically meaningful: in combination with L-glutamate, AKG can reduce levels of ammonia formed in the brain, muscles, and kidneys, as well as help balance the body's nitrogen chemistry and prevent nitrogen excess in body tissues and fluids. Alpha-ketoglutarate is a precursor of glutamine which contributes to muscle repair, prevents protein catabolism, improves nitrogen retention, functions as an immunomodulatory molecule, and takes part in proper function of intestines.

3.4 AKG as Cofactor for 2-Oxoglutarate-Dependent Dioxygenases (2-OGDDs)

AKG functions as an energy donor, a precursor in the amino acid biosynthesis, a signalling molecule, as well as a regulator of epigenetic processes and cellular signalling via protein binding. AKG is an obligatory co-substrate for 2-oxoglutarate-dependent dioxygenases, which catalyse hydroxylation reactions on various types of substrates. These substrates include proteins, nucleic acids, lipids, and metabolic intermediates.

Specific enzymatic targets include: AKG regulates the activity of prolyl-4 hydroxylase, which controls the biosynthesis of collagen, a component of bone tissue. AKG also affects the functioning of prolyl hydroxylases, which in turn influences the function of the hypoxia-inducible factor (HIF), an important transcription factor in cancer development and progression. Additionally, it affects the functioning of enzymes that influence epigenetic modifications of chromatin: ten–eleven translocation hydroxylases involved in DNA demethylation and the Jumonji C domain containing lysine demethylases, which are the major histone demethylases. Thus, it regulates gene expression.

3.5 Antioxidant and Anti-Peroxynitrite Properties

AKG has a great effect on suppressing the production of oxygen free radicals and preventing peroxidative damage of lipids by participating in nonenzymatic oxidative decarboxylation during the decomposition of hydrogen peroxide. Laboratory studies have further examined AKG as a potential scavenger of peroxynitrite (ONOO⁻), a highly reactive oxidant implicated in atherosclerosis, neurodegeneration, and sepsis. Alpha-ketoglutarate (αKG) is a known potential highly antioxidative agent for radical oxidative species such as peroxides. The question arises as to whether αKG is also a potential scavenger of ONOO⁻ and a potential protector against ONOO⁻-mediated nitration of proteins.

3.6 mTOR, AMPK, and Cellular Energy Signaling

Dietary supplementation with AKG improves energy status by modulating the AMP-activated protein kinase (AMPK) signaling pathway in the small intestine. An exogenous supply of alpha-ketoglutarate through a supplement could increase Krebs cycle flux, thus increasing the rate of acetyl-CoA oxidation. Additionally, glutamate and arginine — both products of AKG metabolism — trigger mTOR signaling pathway which activates anabolic processes in the cell.

3.7 Epigenetic Regulation and Aging Biology

AKG is involved in various fundamental processes, including central metabolism, collagen synthesis, epigenetic regulation, and stem cell proliferation. Its role as a co-substrate for TET (ten-eleven translocation) hydroxylases and Jumonji-C domain histone demethylases places it at a biochemical intersection between metabolism and gene expression. As an antioxidant, AKG interferes in nitrogen and ammonia balance, and affects epigenetic and immune regulation. These pleiotropic functions of AKG suggest it may also extend human healthspan.

3.8 Valine's Independent Mechanisms

Valine is necessary for immunological function, blood sugar homeostasis, neurotransmitter synthesis, muscle development, energy generation during exercise, and maintaining the body's nitrogen balance. BCAAs are rarely metabolized by the liver because the expression of BCAT, which acts to remove amino groups in the first step of any amino acid catabolism, is very low. This metabolic property allows dietary BCAAs to be delivered effectively in intact forms to muscular tissues. BCAAs stimulate the building of protein in muscle and possibly reduce muscle breakdown.

4. Scientific Evidence by Area of Use

4.1 Skeletal Muscle Health, Exercise Performance, and Muscle Protein Synthesis

Evidence overview: Preliminary; primarily animal and in vitro; limited human clinical data.

A 2024 narrative review explored AKG's potential therapeutic applications in skeletal muscle health and exercise performance, focusing on its mechanisms for promoting muscle regeneration and counteracting muscle atrophy. AKG supports muscle recovery by stimulating muscle satellite cells (MuSCs) and macrophage polarization, aiding muscle repair and reducing fibrosis. Additionally, AKG shows promise in preventing muscle atrophy by enhancing protein synthesis, inhibiting degradation pathways, and modulating inflammatory responses, making it relevant in conditions like sarcopenia, cachexia, and injury recovery. For athletes and active individuals, AKG supplementation has, in certain studies, enhanced endurance, reduced fatigue, and supported faster post-exercise recovery.

However, the human evidence base is weak. Much of the current evidence comes from preclinical studies or small-scale clinical trials, and the underlying mechanisms by which AKG exerts its effects are not fully understood. Additionally, there is a need for more rigorous clinical trials to determine the efficacy and safety of AKG supplementation, especially in diverse populations, including senior citizens, individuals with muscle disorders, and athletes.

With respect to BCAA supplementation more broadly (which includes valine): BCAA supplements are sometimes used to build muscle, improve physical performance, or help with recovery after a concussion or brain injury. But their benefits for any use are not well defined.

For the specific AKG-arginine combination (AAKG) as a proxy for AKG's exercise effects, one randomized controlled study (Wax et al., 2012; n=16) found that acute AAKG supplementation provides no ergogenic benefit on 1RM or TLV as measured by the standard barbell bench press and leg press, regardless of the subjects' training status. The evidence for AKG and valine co-supplementation specifically in exercise settings remains unpublished in the peer-reviewed literature as of the time of this writing.

4.2 Wound Healing and Surgical Recovery

Evidence overview: Moderate for AKG-containing compounds; older human studies in clinical nutrition settings; limited direct data for the valine–AKG pairing.

A few studies published in the 1980s and 1990s in humans suggested the potential benefits of AKG in muscle growth, wound healing, and in promoting faster recovery after surgery. Ornithine alpha-ketoglutarate (OKG), rather than valine alpha-ketoglutarate, was the primary clinical formulation studied in this context. One well-cited report indicated that 20 g of ornithine alpha-ketoglutarate (OKG) daily reduced wound closure time by approximately 35% and halved nitrogen losses in burn patients. The effect of AKG on wound healing, particularly in burn victims, has been investigated in humans, with AKG shown to contribute to faster wound healing and less scarring.

Several studies have shown cardioprotective effects of AKG. During heart surgery, myocardial AKG concentration is critically low, hence cardiac cells are in a low energy state, leading to myocardial ischemic injury. One clinical trial showed that the addition of 28 g of AKG to cardioplegic blood reduces the appearance of ischemic biomarkers, such as creatine kinase.

The AKG-valine combination specifically has not been the subject of dedicated wound-healing clinical trials. The wound-healing evidence is therefore best attributed to AKG's role as a glutamine precursor and collagen biosynthesis co-factor, rather than to any demonstrated valine–AKG synergy.

4.3 Bone Health

Evidence overview: Mechanistically plausible; one randomized controlled trial with Ca-AKG in postmenopausal women; preliminary.

The broadly described positive effect of AKG on bone tissue suggests its potential application in prevention of bone formation disorders, in the treatment of diseases with progressive loss of bone mass, such as osteoporosis, or in improving the body's bone mass. The mechanism involves AKG's role as a co-substrate for prolyl hydroxylase: AKG is an obligatory co-substrate for 2-oxoglutarate-dependent dioxygenases, which catalyse hydroxylation reactions on various types of substrates. It regulates the activity of prolyl-4 hydroxylase, which controls the biosynthesis of collagen, a component of bone tissue.

The most direct human trial in this area used Ca-AKG: a randomized, double-blind, placebo-controlled study with 76 postmenopausal women with osteopenia investigated the effect of Ca-AKG (6 g AKG and 1.68 g Ca per day) over a period of 6 months; the results showed a significant decrease in serum levels of C-terminal cross-linked telopeptide of type I collagen (CTX), a marker for bone resorption, by up to 37% after 24 weeks. This is a single trial in a specific population, and it used calcium AKG rather than the valine–AKG form, limiting direct extrapolation.

A 2025 animal study (controlled laboratory, 48 female Sprague-Dawley rats) explored locally administered AKG in the setting of postmenopausal rotator cuff repair. Alpha-KG supplementation along with surgery may enhance rotator cuff repair for patients with osteoporosis complications, according to the investigators. This was a preclinical study and cannot be directly translated to human supplementation.

4.4 Aging, Longevity, and Biological Age Markers

Evidence overview: Promising in animal models; early-phase human data; no confirmed clinical outcomes in humans as of current sources.

A pivotal 2020 study published in Cell Metabolism investigated calcium AKG supplementation in C57BL/6 mice. AKG (delivered in the form of a calcium salt, CaAKG), a key metabolite in the TCA cycle, was shown to significantly extend lifespan and healthspan in mice. CaAKG promotes a longer, healthier life associated with a decrease in levels of systemic inflammatory cytokines. The authors propose that induction of IL-10 by dietary AKG suppresses chronic inflammation, leading to health benefits. By simultaneously reducing frailty and enhancing longevity, AKG, at least in the murine model, results in a compression of morbidity.

Preceding animal evidence had demonstrated lifespan-extending effects in simpler organisms. Previous work in D. melanogaster and C. elegans demonstrated that aKG could regulate longevity in short-lived species. In Drosophila, AKG was shown to extend lifespan through pathways associated with mTOR and AMPK signaling, two central regulators of energy and stress response.

AKG levels in the body decline significantly with age — studies show that the concentration at age 80 is only about 10% of the value present at age 40. This age-related decline has sparked scientific interest in Ca-AKG as a potential agent for influencing age-related processes.

For human aging specifically, a registered clinical trial, the ABLE Study (Alpha-ketoglutarate supplementation and BiologicaL agE), is examining Ca-AKG supplementation: this is a double-blind randomized placebo-controlled study investigating the potential of Ca-Alpha-Ketoglutarate supplementation to reduce DNA methylation age and the effect on clinical and biological outcomes, screening 40–60-year-old individuals based on DNA methylation clocks including Hannum, Horvath's, GrimAge and PhenoAge. So far there are no recently published studies demonstrating the role of AKG in treating aging and age-related diseases; hence, further clinical studies are required to better understand the role of AKG in humans.

4.5 Nitrogen Balance, Protein Metabolism, and Renal Disease

Evidence overview: Moderate; specific to hemodialysis and post-surgical settings; evidence for AKG, not VAKG specifically.

In clinical trials with hemodialysis patients, AKG supplementation increased blood levels of arginine (an amino acid involved in blood vessel dilation and wound healing) while decreasing urea, a waste product of protein metabolism. That shift suggests AKG nudges nitrogen toward useful amino acid production rather than waste.

By virtue of its role in the amino acid synthesis pathway, alpha-ketoglutarate exerts strong regulatory control over protein metabolism. Previous studies demonstrated its potency in conserving endogenous glutamine pools and increasing glutamine synthesis, which have particular benefits in clinical nutrition and metabolic care by countering trauma-induced catabolism.

4.6 Hepatic Encephalopathy (BCAAs, Including Valine)

Evidence overview: Moderate; for BCAAs collectively (not valine–AKG specifically).

BCAAs are used for reduced brain function in people with advanced liver disease and for a movement disorder often caused by antipsychotic drugs. They are also commonly used to improve athletic performance, prevent fatigue, and reduce muscle breakdown, but there isn't enough reliable information to support these other uses. Taking BCAAs by mouth seems to improve liver function in people with poor brain function caused by liver disease. This evidence supports BCAAs as a class; the contribution of valine specifically, and of its pairing with AKG, has not been individually isolated in published clinical trials.

4.7 Glucose Metabolism and Insulin Sensitivity

Evidence overview: Preliminary; primarily animal models; conflicting signals for valine specifically.

Recent studies reported that elevated plasma BCAA (leucine, isoleucine, and valine) concentrations are related to insulin resistance, resulting in a high diabetic risk. AKG (IUPAC name: 2-oxopentanedioic acid), an intermediate of the tricarboxylic acid cycle, is known as a substrate for BCAA transaminases and plays an important role in BCAA catabolism. Lower intracellular AKG concentration and higher BCAA concentration were observed in type 2 DM and obesity compared with healthy groups.

One study in diabetic mice found that mice in the DM + AKG group were administered 1% AKG in drinking water for 6 weeks, and the non-fasting plasma glucose level was significantly higher in the diabetic group than in the control and DM + AKG groups (P < 0.05). This is animal-only evidence.

With regard to valine's individual effect on insulin sensitivity, one preclinical study noted that Val did not demonstrate similar blood glucose-lowering benefits as leucine and isoleucine and was more likely to contribute to insulin resistance in mice fed a high-fat diet, indicating its possible role in fat metabolism. These conflicting signals caution against assuming that the valine component of VAKG universally benefits glucose homeostasis.

4.8 Immune Function

Evidence overview: Mechanistic and animal data only; no human clinical trials specific to VAKG.

AKG's pleiotropic activities include studies conducted in states of protein deficiency and oxidative stress conditions. It is also discussed as an immunomodulatory agent. AKG is a precursor of glutamine and glutamate, energy sources for enterocytes and various immune cells, and an antioxidant with roles in immune homeostasis, aging, protein synthesis, and bone development. Animal studies have demonstrated that AKG can modulate macrophage function and suppress inflammatory cytokines, particularly through IL-10 induction; however, controlled human clinical evidence for immune benefits of VAKG is absent.

5. Body Systems and Health Areas Associated with VAKG

Musculoskeletal system: Protein synthesis, muscle atrophy prevention, sarcopenia, post-surgical muscle loss, exercise recovery
Connective tissue and bone: Collagen biosynthesis (via prolyl hydroxylase co-factor activity), osteoporosis, bone remodeling
Energy metabolism: TCA/Krebs cycle flux, mitochondrial function, ATP generation
Nitrogen homeostasis: Ammonia scavenging, nitrogen balance in high-protein intake states, renal disease
Epigenetics and aging biology: DNA demethylation, histone demethylation, biological age markers, healthspan
Immune system: Glutamine precursor for lymphocytes and macrophages, IL-10 modulation
Hepatic and neurological: BCAA-based support in hepatic encephalopathy
Skin: Collagen-related skin quality, wound healing
Cardiovascular: Myocardial protection during ischemia (investigated with IV/infusion AKG, not oral VAKG)

6. Dosage Forms and Dosages Reported in Studies

No single authoritative clinical protocol exists for "valine alpha-ketoglutarate" as a combined supplement. The dosages below reflect what has been studied for the individual components or closely related formulations in peer-reviewed sources.

AKG — postmenopausal osteopenia (Ca-AKG form): 6 g AKG and 1.68 g Ca per day over a period of 6 months, studied in a randomized, double-blind, placebo-controlled trial of 76 postmenopausal women with osteopenia.
AKG — animal aging model: Dietary supplemented 2% CaAKG (w/w) increased survival in two independent cohorts of aged mice, with median lifespan and survival significantly extended by 16.6% and 19.7% from inception of CaAKG feeding in the first cohort of female mice.
AKG — animal diabetes model: Mice were administered 1% AKG in drinking water for 6 weeks.
AKG — general tolerability upper range (review-reported): The safety record is strong, with doses up to 6 grams per day generally well tolerated.
ABLE clinical trial (human, ongoing): The ABLE Study is testing 1 g daily Ca-AKG versus placebo for DNA methylation age effects.
Valine (BCAA context, estimated requirement): It is estimated that adults should consume about 68 mg/kg daily (valine: 19 mg/kg); other estimates suggest that adults might actually need 144 mg/kg daily.
Ornithine AKG (OKG) — wound healing (burn patients): 20 g/day, as cited in the clinical nutrition literature, resulting in reduced wound closure time.
AKG — cardiac surgery (IV/infusion use): One clinical trial showed that the addition of 28 g of AKG to cardioplegic blood reduces the appearance of ischemic biomarkers.

Supplements containing alpha-ketoglutarate are available over-the-counter, but their benefits for any use are not well defined. Oral supplement products are most commonly presented in capsule or powder form, frequently at 500 mg–1,000 mg AKG per serving, though the clinical relevance of these specific doses is not established by rigorous human trials.

7. Safety Considerations and Interactions

7.1 General Tolerability

AKG supplements seem to be well tolerated, though there is not enough research to know what common side effects they may cause. The available human data, particularly from clinical nutrition use in surgical and renal patients at doses up to several grams per day, has not revealed serious adverse effects. Although BCAAs appear to be well tolerated, there is not enough research to know what side effects they may cause.

7.2 Regulatory Status

The FDA has not reviewed alpha-ketoglutarate for safety and effectiveness as a dietary supplement. It is sold under the regulatory framework of the Dietary Supplement Health and Education Act (DSHEA) in the United States, meaning pre-market efficacy or safety review is not required.

7.3 Contraindications: Maple Syrup Urine Disease (MSUD)

Maple Syrup Urine Disease (MSUD) is an absolute contraindication for BCAA supplementation. MSUD is a rare genetic disorder caused by deficient activity of the branched-chain α-keto acid dehydrogenase (BCKDH) enzyme complex. Without functional BCKDH, leucine, isoleucine, valine, and their keto-acid metabolites accumulate to neurotoxic levels in blood and cerebrospinal fluid. BCAA restriction — not supplementation — is the primary dietary treatment for MSUD. Any form of BCAA supplementation in individuals with MSUD is clinically dangerous and should never be undertaken.

Additionally, valine deficiency can lead to Valinemia, a rare metabolic condition characterized by low levels of the enzyme valine transaminase, which is essential for the body to break down valine, and may include symptoms such as loss of appetite, excessive drowsiness, poor growth, neurological issues, developmental delays, lack of muscle tone, and elevated levels of valine in blood and urine.

7.4 ALS and Motor Neuron Disease

A safety signal of particular note involves high-dose BCAA supplementation in amyotrophic lateral sclerosis (ALS). The Italian ALS Study Group trial (1993, Journal of Neurology) examined high-dose BCAAs at 12 g three times daily in ALS patients; the trial was discontinued early due to an accelerated rate of respiratory muscle decline and higher mortality in the BCAA supplementation arm versus placebo. This finding pertains to a specific high-dose regimen in a patient population with existing motor neuron disease, and does not generalize to standard supplementation in healthy individuals; however, the unresolved mechanistic concern justifies caution against BCAA supplementation in any form of motor neuron disease.

7.5 Multi-Component Product Interactions

Some products contain alpha-ketoglutarate along with other substances, such as arginine, ornithine, and calcium. These other substances may cause different effects, side effects, and interactions. The combination with calcium (Ca-AKG) is the form most studied in clinical contexts and introduces considerations around calcium intake totals, particularly in individuals already consuming calcium supplementation or with hypercalcemia risk.

7.6 Elevated Plasma BCAAs and Insulin Resistance

Recent studies reported that elevated plasma BCAA concentrations are related to insulin resistance, resulting in a high diabetic risk. Chronic high-dose BCAA supplementation — including valine — in the context of high-fat diets has raised metabolic concerns in preclinical models. Whether physiological oral supplementation doses produce similar effects in humans is not established.

7.7 Lack of Data in Vulnerable Populations

Valine supplements should be avoided in pregnant and breastfeeding mothers unless advised to do so by a healthcare professional. Pediatric dosing data are not established. The tolerable upper intake level (UL) for valine has not been formally set: the UTL of valine is not established.

7.8 AKG as Epigenetic Regulator — Theoretical Oncological Consideration

AKG affects the functioning of prolyl hydroxylases, which in turn influences the function of the hypoxia-inducible factor (HIF), an important transcription factor in cancer development and progression. Because AKG acts as a co-substrate for the same enzymes that oncometabolites (such as 2-hydroxyglutarate) inhibit, it has been investigated for potential anti-tumorigenic roles as well as potential pro-tumorigenic interactions. The regulatory role of AKG and its structural analogues in carcinogenesis, as well as the results of studies of AKG as an anticancer agent, are discussed in the literature, but no clinical guidance has yet emerged from this area.

8. Evidence Quality Summary

The scientific literature relevant to "valine alpha-ketoglutarate" must be understood as resting on two distinct but overlapping bodies of evidence: (1) the biochemistry and clinical use of alpha-ketoglutarate in various salt forms (free acid, calcium salt, ornithine salt, arginine salt), which is moderately characterized; and (2) the broader BCAA and valine literature. As a defined, combined ingredient:

There are no dedicated, powered randomized controlled trials specifically studying "valine alpha-ketoglutarate" as a combined supplement in humans as of current sources.
The mechanistic rationale — based on the valine–AKG transamination equilibrium — is biochemically sound and well-described in primary literature.
The strongest clinical evidence for AKG supplementation as a class relates to bone resorption markers in postmenopausal women (one RCT, Ca-AKG) and the clinical nutrition use of ornithine-AKG in surgical recovery (older studies, 1980s–1990s).
Animal and in vitro evidence for AKG in aging, muscle health, and metabolic regulation is substantial; translation to humans requires further investigation.
So far there are no recently published studies demonstrating the role of AKG in treating aging and age-related diseases; hence, further clinical studies are required to better understand the role of AKG in humans.